CAS: 3424-98-4; 1-((2S,4R,5S)-4-Hydroxy-5-(Hydroxymethyl)Tetrahydrofuran-2-yl)-5-Methylpyrimidine-2,4(1H,3H)-Dione

相似化合物

50-89-5 40733-28-6 40733-27-5

上下游产品

2',3',5'-tri-O-benzoyl-5-methyl-L-uridine 3',5'-O-(1,1,3,3-tetraisopropyldisiloxan-1,3-diyl)-L-thymidine 3',5'-di-O-levulinoyl-β-L-thymidine 1-O-acetyl-2,3,5-tri-O-benzoyl-β-L-ribofuranose 5'-O-(4-4'-dimethoxytrityl)thymidine 3'-O-(4,4'-dimethoxytriphenylmethyl)-5'-O-fluorenylmethoxycarbonylthymidine 3',5'-di-O-acetyl-5-((5-hydroxy-3-methyl-1-phenyl-1H-pyrazol-4-yl)(3-methyl-5-oxo-1-phenyl-4,5-dihydro-1H-pyrazol-4-yl)methyl)-2'-deoxy-β-L-uridine 5-((5-hydroxy-3-methyl-1-phenyl-1H-pyrazol-4-yl)(3-methyl-5-oxo-1-phenyl-4,5-dihydro-1H-pyrazol-4-yl)methyl)-2'-deoxy-β-L-uridine

3',5'-Di-O-Acetyl-β-L-Thymidine置于sodium Hydroxide,乙醇,水,溶剂黄146体系中,用 乙醇 用作溶剂,化学反应 48.5H,反应生成替比夫定
参考文献:Process For Preparing L-Nucleic Acid Derivatives And Intermediates Thereof
标题:Process For Preparing L-Nucleic Acid Derivatives And Intermediates Thereof
摘要:已找到一种新的方法,用于生产2,2'-去水-1-(β-L-阿拉伯呋喃糖基)胸腺嘧啶作为一种新的有用中间化合物.另外还发现了一种新的方法,可从2,2'-去水-1-(β-L-阿拉伯呋喃糖基)胸腺嘧啶中生产胸腺嘧啶.根据这些方法,合成各种l-核酸衍生物,这些衍生物的合成直到现在都很困难,现在是可能的.

专利信息

专利号:WO-2022256490-A9
优先权日:2021-06-03
标题:Improved synthesis of phosphoramidates for the treatment of hepatitis b virus
发明人：LOCKWOOD MARK
权利人:ANTIOS THERAPEUTICS INC
摘要:The synthesis of phosphoramidate prodrugs useful in the treatment of viral infections is disclosed. Specifically, an improved synthesis of phosphoramidate nucleotides useful in the treatment of Hepatitis B virus is disclosed.

专利号:US-11858953-B2
优先权日:2018-04-04
标 题:Compositions and methods for synthesis of phosphorylated molecules
发明人：CHAPUT JOHN; LIAO JEN-YU; BALA SAIKAT
权利人:UNIV CALIFORNIA
摘要:The invention provides compositions and methods for synthesis of phosphorylated organic compounds, including nucleoside triphosphates.

专利号:US-9334273-B1
优先权日:2014-03-05
标题:Efficient and stereoselective synthesis of 2′-fluoro-6′-methylene-carbocyclic adenosine (FMCA)
发明人：CHU DAVID C K; SINGH UMA S
权利人:UNIV GEORGIA
摘要:The invention provides a new convergent approach for the synthesis of 2′-fluoro-6′-methylene-carbocyclic adenosine (FMCA) from a readily available starting material (Vince lactam) in fourteen steps. An efficient and practical methodology for stereospecific preparation of a versatile carbocyclic key intermediate, D -2′-fluoro-6′-methylene cyclopentanol by diazotization, elimination, stereoselective epoxidation, fluorination and oxidative reduction of the Vince lactam in twelve steps is also provided.

专利号:US-2015376219-A1
优先权日:2014-06-30
标题 :Selective Preparations of Purine Nucleosides and Nucleotides: Reagents and Methods
发明人：ZHONG MINGHONG
权利人:ZHONG MINGHONG
摘要:A process of regiospecific synthesis of N-9 purine nucleoside analogs in either solution or solid phase synthesis is described. The introduction of the sugar moiety or its analogue on to a 6-heteroarylium purine or its mesomeric betaine so that formation of only the N-9 position regioisomers of the purine nucleoside analogs (either D or L enantiomers) is obtained. This regiospecific introduction of the sugar moiety allows the synthesis of purine nucleoside analogs in high yields without formation of the N-7-positional regioisomers, while the 6-heteroaryliums are leaving groups facilitated for nucleophilic displacement. Solid supported 6-heterarylium purine bases can be used for purine based library synthesis and synthesis of nucleotide monophosphates and polyphosphates. Processes for providing novel 6-heteroarylium purines and their corresponding mesomeric betaines for the regiospecific synthesis of N-9 purine nucleoside analogs and nucleotides are described.

专利号:US-7125983-B2
优先权日:2000-11-29
标题:L-nucleic acid derivatives and process for the synthesis thereof
发明人：IIZUKA HAJIME; TOGASHI KAZUHIKO; SUZUKI TSUNEJI
权利人:MITSUI CHEMICALS INC
摘要:A novel method has been found to produce 2,2′-anhydro-1-(β-L-arabinofuranosyl)thymine as a novel useful intermediate compound. A novel method has been further found to produce thymidine from 2,2′-anhydro-1-(β-L-arabinofuranosyl)thymine. A novel method has been further found to L-2′-deoxyribose derivatives as a useful synthetic intermediate through L-2,2′-anhydro-5,6-dihydrocyclouridine derivative. According to these methods, synthesis of various L-nucleic acid derivatives, synthesis of which has been difficult till now.

专利号:EP-1543168-B1
优先权日:2002-09-27
标 题:Method for assaying replication of hbv and testing susceptibility to drugs
发明人：DURANTEL DAVID; DURANTEL SANDRA; TREPO CHRISTIAN; ZOULIM FABIEN
权利人:INST NAT SANTE RECH MED
摘要:Measuring the replication capacity of hepatitis B virus (HBV), e.g. HBV in a biological sample, possibly in the presence of a pharmaceutical product, and particularly an antiviral agent, is new. Measuring the replication capacity of hepatitis B virus (HBV), e.g. HBV present in a biological sample, possibly in the presence of a pharmaceutical product, particularly an antiviral agent, comprises: (a) optional extraction of nucleic acids contained in the sample; (b) PCR amplification of HBV nucleic acids using at least 2 primer pairs to obtain at least 2 amplified HBV genomic fragments representing more-than-full-length HBV genome; (c) cloning the fragments obtained into a vector; (d) transfecting or transducing susceptible cells with the vector; (e) culturing the transfected or transduced cells in conditions allowing synthesis of HBV pregenomic RNA (pgRNA) from the cloned HBV DNA; (f) optionally treating the cultured cells with a pharmaceutical product, particularly an antiviral agent; and (g) determining the replication capacity of the HBV, and the effect of any pharmaceutical product used on viral gene expression and/or viral replication. Independent claims are also included for: (1) a polynucleotide useful as primer for HBV amplification, comprising a sequence selected from 21 sequences of 23-42 bp (SEQ ID NO: 1-21) given in the specification; (2) a primer pair for HBV amplification comprising: (a) a forward primer comprising SEQ ID NO: 1-12, and/or a reverse primer comprising SEQ ID NO: 13 or SEQ ID NO: 14; (b) a forward primer comprising SEQ ID NO: 15 and/or 16 or 19, and a reverse primer comprising SEQ ID NO: 17 and/or SEQ ID NO: 18; (c) a forward primer comprising SEQ ID NO: 19, and a reverse primer comprising SEQ ID NO: 17 and/or SEQ ID NO: 18; or (d) a forward primer comprising SEQ ID NO: 20 or 22, and a reverse primer comprising SEQ ID NO: 21 or 23; (3) kits for HBV amplification, comprising a primer pair of (2); (4) a vector comprising a more-than-full length HBV genome as defined above, and a promoter modified in the 5' by the presence of a restriction site in the 5' of the +1 of transcription, where the +1 of transcription of the more-than-full length HBV genome and of the promoter are fused, and the promoter controls the synthesis of a pgRNA from the more-than-full length HBV genome post-cell-transfection; and (5) a baculovirus or cell line comprising the vector. ACTIVITY : Virucide. MECHANISM OF ACTION : None given.